| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1878085 | Applied Radiation and Isotopes | 2010 | 5 Pages |
Abstract
A new phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol) was developed as a boron carrier for the boron neutron capture therapy (BNCT) of hepatoma in Taiwan. The biodistribution of both PBAD-lipiodol and BPA-fructose was assayed in GP7TB hepatoma-bearing rat model. The highest uptake of PBAD-lipiodol was found at 2 h post injection. The application of BNCT for the hepatoma treatment in tumor-bearing rats is suggested to be 2–4 h post PBAD-lipiodol injection.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
A.H. Liao, F.I. Chou, Y.C. Kuo, H.W. Chen, J.J. Kai, C.W. Chang, F.D. Chen, J.J. Hwang,